---
title: "Avacta Group PLC has announced that the first patient has been dosed in the US in the AVA6000 Phase 1 trial."
publisher: "Share Talk"
author: "sharetalk"
published: "2023-04-27T09:00:56+00:00"
modified: "2023-04-27T09:00:56+00:00"
date: 2023-04-27
canonical: "https://www.share-talk.com/avacta-group-plc-has-announced-that-the-first-patient-has-been-dosed-in-the-us-in-the-ava6000-phase-1-trial/"
category: "Healthcare"
categories: ["Healthcare", "Pharmaceutical"]
tags: ["Abingdon Health", "AffyXell Therapeutics", "antigen", "Avacta Group", "AVCT", "Biotherapeutics", "Chris Yates", "clinical", "COVID-19", "Cytiva", "Daewoong Pharmaceutical", "diagnostic", "Doncaster", "Europe", "LG Chem Life Sciences", "Pharma", "radiopharmaceuticals", "saliva test", "SARS-COV-2", "Sengho Jeon", "Share Talk", "South Korea", "therapeutic", "UK", "validation", "York"]
image: "https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1"
format: "news"
language: "en-GB"
---

# Avacta Group PLC has announced that the first patient has been dosed in the US in the AVA6000 Phase 1 trial.

**Published:** April 27, 2023
**Author:** sharetalk
**Categories:** Healthcare, Pharmaceutical
**Tags:** Abingdon Health, AffyXell Therapeutics, antigen, Avacta Group, AVCT, Biotherapeutics, Chris Yates, clinical, COVID-19, Cytiva, Daewoong Pharmaceutical, diagnostic, Doncaster, Europe, LG Chem Life Sciences, Pharma, radiopharmaceuticals, saliva test, SARS-COV-2, Sengho Jeon, Share Talk, South Korea, therapeutic, UK, validation, York
**Featured image:** ![](https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1)

---

**Avacta Group plc**, a life sciences company that develops targeted oncology drugs and diagnostics, has dosed the first patient in the US as part of its phase 1 multi-center trial to evaluate the safety and tolerability of AVA6000.

This is a novel, tumour-targeted form of doxorubicin and Avacta’s first therapeutic product that is based on the company’s proprietary pre|CISION™ technology, under its Investigational New Drug (IND) Application.

The dose-escalation study for locally advanced or metastatic selected solid tumors, which are known to be FAP-positive, will take place at the Memorial Sloan Kettering Cancer Center in New York. More information on the trial can be found at [www.clinicaltrials.gov](http://www.clinicaltrials.gov/) (NCT04969835).

Dr Alastair Smith, CEO of Avacta Group plc, noted that New York and Seattle US trial sites, along with other locations in the UK and US, would play a crucial role in both the dose escalation and dose expansion phases of the multi-center trial, which is expected to start in the second half of the year.

Dosing the first patient in the US is a significant milestone and reflects the ongoing progress in the ALS-6000-101 clinical trial and the Therapeutics Division as a whole, he added.

---

**Original URL:** https://www.share-talk.com/avacta-group-plc-has-announced-that-the-first-patient-has-been-dosed-in-the-us-in-the-ava6000-phase-1-trial/
*Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*